(S020) The Role of Adjuvant Radiotherapy in T4 Colon Cancer

Publication
Article
OncologyOncology Vol 30 No 4_Suppl_1
Volume 30
Issue 4_Suppl_1

In this large population dataset, adjuvant radiation was associated with an improvement in OS in a modern cohort of patients. Patients with distal tumors, higher-grade disease, negative lymph nodes, and larger tumors may derive a greater benefit with radiation.

Talha Shaikh, MD, Thomas M. Churilla, MD, Colin T. Murphy, MD, Michael Hall, MD, MS, Elin R. Sigurdson, MD, PhD, Joshua E. Meyer, MD; Fox Chase Cancer Center

BACKGROUND: The role of adjuvant radiation for T4 colon adenocarcinoma is controversial. We assessed the impact of adjuvant radiation on treatment outcomes in a large national dataset.

MATERIALS AND METHODS: The Surveillance, Epidemiology, and End Results (SEER) registry was queried from 1988–2012 for patients aged > 18 years diagnosed with T4 colon adenocarcinoma who underwent curative surgery. The primary endpoints were overall survival (OS) and cancer-specific survival (CSS) for patients treated with or without adjuvant radiation. Survival was assessed utilizing the Kaplan-Meier method and a Cox proportional hazards model.

RESULTS: A total of 29,830 patients were identified; 1,877 (6.3%) patients received adjuvant radiation. There was no difference in OS (P = .384) with adjuvant radiation. Patients receiving radiation had a worse CSS than patients who received no adjuvant radiation (P < .001). On examination of a modern cohort of patients treated from 2004–2012, patients receiving adjuvant radiation had an improvement in OS compared with patients receiving no radiation (P < .001), and there was a trend toward improved CSS in patients receiving adjuvant radiation (P = .053). On multivariable analysis, adjuvant radiation remained associated with OS (hazard ratio [HR], 0.88 [95% CI, 0.78–0.99]; P = .034). Subgroup analysis demonstrated an OS benefit with radiation in patients with distal tumors (P = .002), grade 3/4 disease (P = .006), grade 2 disease (P = .012), negative lymph nodes (P < .001), and tumor size > 5 cm (P < .001).

CONCLUSION: In this large population dataset, adjuvant radiation was associated with an improvement in OS in a modern cohort of patients. Patients with distal tumors, higher-grade disease, negative lymph nodes, and larger tumors may derive a greater benefit with radiation.

Proceedings of the 98th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(S002) A 15-Year Review of Radiation Therapy for Keloids at Two Institutions
(S003) Single-Fraction Radiation Therapy for the Treatment of Multiple Myeloma Bony Metastases Provides Pain Control and Decreases Time to Chemotherapy
(S001) Prognostic Value of Pretreatment Serum Inflammatory Markers in Patients Receiving Radiation Therapy for Oropharyngeal Cancer
(S004) Trend in Second Malignancy Risk for Head and Neck Cancer With Increased Utilization of IMRT: Analysis of SEER Database
(S005) Comparison of Legal Needs of a Group of Patients With Cancer: Economic and Geographic Factors
(S006) Mission Improvement: Lessons From Initiating a Resident-Led Quality Improvement Project on Smoking Cessation at a County Hospital
(S007) Results of a Phase II Trial Using Cetuximab Plus Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma
(S008) The Effect of Simulation and Treatment Delays for Patients With Oropharyngeal Cancer Receiving Definitive Radiation Therapy in the Era of Risk Stratification Using Smoking and Human Papilloma Virus Status
(S009) Intensity-Modulated Radiation Therapy With Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on Three-Year Toxicity
(S011) Comparative Study Between Ileal Conduit and Indiana Pouch After Cystectomy for Patients With Carcinoma of Urinary Bladder
(S010) Computed Tomography–Assessed Measures of Bone Mineral Density and Muscle Mass as Predictors of Survival in Men With Prostate Cancer
(S012) Quantitative Imaging to Evaluate the Malignant Potential of Pancreatic Cysts
(S013) Spine Stereotactic Radiosurgery With Concurrent Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
(S014) The Impact of Radiation Therapy on Survival in Surgically Resected, High-Risk Patients With Ampullary Adenocarcinoma: A Population-Based Analysis
(S016) The Impact of Stereotactic Body Radiation Therapy on Overall Survival in Patients With Locally Advanced Pancreatic Cancer
Recent Videos
Preliminary phase 2 trial data show durvalumab plus lenalidomide was superior to durvalumab alone in refractory/advanced cutaneous T-cell lymphoma.
Performance status, age, and comorbidities may impact benefit seen with immunotherapy vs chemotherapy in patients with breast cancer.
Developing odronextamab combinations following CAR T-cell therapy failure may help elicit responses in patients with diffuse large B-cell lymphoma.
Cytokine release syndrome was primarily low or intermediate in severity, with no grade 5 instances reported among those with diffuse large B-cell lymphoma.
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.
Patients with ESR1+, ER+/HER2– breast cancer resistant to chemotherapy may benefit from combination therapy with elacestrant.
Related Content